2J21
Human p53 core domain mutant M133L-V203A-N239Y-N268D-R282W
Summary for 2J21
Entry DOI | 10.2210/pdb2j21/pdb |
Related | 1A1U 1AIE 1C26 1DT7 1GZH 1H26 1HS5 1JSP 1KZY 1MA3 1OLG 1OLH 1PES 1PET 1SAE 1SAF 1SAG 1SAH 1SAI 1SAJ 1SAK 1SAL 1TSR 1TUP 1UOL 1XQH 1YCQ 1YCR 1YCS 2AC0 2ADY 2AHI 2ATA 2B3G 2BIM 2BIN 2BIO 2BIP 2BIQ 2F1X 2FEJ 2J0Z 2J10 2J11 2J1W 2J1X 2J1Y 2J1Z 2J20 3SAK |
Descriptor | CELLULAR TUMOR ANTIGEN P53, ZINC ION (3 entities in total) |
Functional Keywords | second-site suppressor mutation, disease mutation, nuclear protein, phosphorylation, tumor suppressor, alternative splicing, li-fraumeni syndrome, li- fraumeni syndrome, host-virus interaction, transcription, metal-binding, anti-oncogene, dna-binding, transferase, polymorphism, glycoprotein, zinc, activator, apoptosis, cell cycle, acetylation, p53 dna-binding domain, transcription regulation, superstable mutant, dna-binding protein |
Biological source | HOMO SAPIENS (HUMAN) |
Cellular location | Cytoplasm. Isoform 1: Nucleus. Isoform 2: Nucleus. Isoform 3: Nucleus. Isoform 4: Nucleus. Isoform 7: Nucleus. Isoform 8: Nucleus. Isoform 9: Cytoplasm: P04637 |
Total number of polymer chains | 2 |
Total formula weight | 49370.53 |
Authors | Joerger, A.C.,Fersht, A.R. (deposition date: 2006-08-15, release date: 2006-09-20, Last modification date: 2023-12-13) |
Primary citation | Joerger, A.C.,Ang, H.C.,Fersht, A.R. Structural Basis for Understanding Oncogenic P53 Mutations and Designing Rescue Drugs. Proc.Natl.Acad.Sci.USA, 103:15056-, 2006 Cited by PubMed: 17015838DOI: 10.1073/PNAS.0607286103 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (1.6 Å) |
Structure validation
Download full validation report